Drug treatment of obesity

Psychiatric Clinics of North America

Volumn 34, Issue 4, 2011, Pages 871-880

  Bray, George A ^a   Ryan, Donna H ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Diet; Drugs; Obesity; Treatment

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMFEPRAMONE; ANTIOBESITY AGENT; BENZPHETAMINE; EXENDIN 4; INSULIN GLARGINE; LEPTIN; LIRAGLUTIDE; LORCASERIN; METFORMIN; NALTREXONE; PHENDIMETRAZINE; PHENTERMINE; PLACEBO; PRAMLINTIDE; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; TOPIRAMATE;

ABNORMAL FECES COMPOSITION; ANOREXIA; ANXIETY DISORDER; ASTHENIA; ATTENTION DISTURBANCE; BODY MASS; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DYSGEUSIA; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INSOMNIA; JAUNDICE; LIVER INJURY; LOW CALORY DIET; MEMORY DISORDER; METABOLIC SYNDROME X; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; ANTI-OBESITY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BODY WEIGHT; BUPROPION; CHILD; DRUG APPROVAL; DRUG COMBINATIONS; ENERGY INTAKE; FEMALE; FRUCTOSE; HUMANS; HYPOGLYCEMIC AGENTS; ISLET AMYLOID POLYPEPTIDE; LACTONES; MALE; METFORMIN; NALTREXONE; NARCOTIC ANTAGONISTS; OBESITY; PATIENT COMPLIANCE; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYMPATHOMIMETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VENOMS;

EID: 81355153937     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2011.08.013     Document Type: Review

References (38)

1. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
2. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010, 303:242-249.
3. Bray G.A. A guide to obesity and the metabolic syndrome: origins and treatment 2011, CRC Press, Boca Raton (FL).
4. Bray G.A. The low-fructose approach to weight control 2009, Dorrance Publishing, Pittsburgh.
5. Bray G.A., Greenway F.L. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007, 59:151-184.
6. Lam D.D., Pryzdzial M.J., Ridley S.H., et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008, 40:1323-1328.
7. Hendricks E.J., Rothman R.B., Greenway F.L. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) 2009, 17:1730-1735.
8. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155-161. Erratum in: Diabetes Care 2004;27:856.
9. Chanoine J.P., Hampl S., Jensen C., et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005, 293:2873-2883. Erratum in: JAMA 2005;294:1491.
10. Rucker D., Padwal R., Li S.K., et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335:1194-1199.
11. Questions and answers: Orlistat and severe liver injury US Food and Drug Administration, Accessed May 27, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders%20/ucm213040.htm.
12. Snow V., Barry P., Fitterman N., et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005, 142:525-531.
13. He L., Sabet A., Djedjos S., et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009, 137:635-646.
14. Setter S.M., Iltz J.L., Thams J., et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003, 25:2991-3026.
15. Crandall J.P., Knowler W.C., Kahn S.E., et al. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 2008, 4:382-393.
16. Gillies C.L., Abrams K.R., Lambert P.C., et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007, 334:299.
17. Park M.H., Kinra S., Ward K.J., et al. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009, 32:1743-1745.
18. Fontbonne A., Charles M.A., Juhan-Vague I., et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996, 19:920-926. BIGPRO Study Group.
19. Fontbonne A., Diouf I., Baccara-Dinet M., et al. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab 2009, 35:385-391.
20. Avenell A., Broom J., Brown T.J., et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004, 8:1-182.
21. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
22. Knowler W.C., Fowler S.E., Hamman R.F., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
23. Bushe C.J., Bradley A.J., Doshi S., et al. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development?. A systematic review of clinical studies. Int J Clin Pract 2009, 63:1743-1761.
24. Heymsfield S.B., Greenberg A.S., Fujioka K., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999, 282:1568-1575.
25. Ravussin E., Smith S.R., Mitchell J.A., et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009, 17:1736-1743.
26. Edwards C.M., Stanley S.A., Davis R., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001, 281:E155-E161.
27. Amori R.E., Lau J., Pittas A.G., et al. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
28. Heine R.J., Van Gaal L.F., Johns D., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
29. Apovian C., Bergenstal R., Cuddihy R., et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010, 123:468.e9-468.e17.
30. Fineman M.S., Shen L.Z., Taylor K., et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004, 20:411-417.
31. Astrup A., Rössner S., Van Gaal L., et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374:1606-1616.
32. Smith S.R., Weissman N.J., Anderson C.M., et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010, 363:245-256.
33. Gadde K.M., Parker C.B., Maner L.G., et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001, 9:544-551.
34. Anderson J.W., Greenway F.L., Fujioka K., et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res 2002, 10:633-641.
35. Bray G.A., Hollander P., Klein S., et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003, 11:722-733.
36. Gadde K.M., Allison D.B., Ryan D.H., et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:1341-1352.
37. Greenway F.L., Whitehouse M.J., Guttadauria M., et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009, 17:30-39.
38. Greenway F.L., Fujioka K., Plodkowski R.A., et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010, 376:595-605.